NewLink Genetics Corporation (NLNK) EPS Estimated At $-0.55

April 21, 2018 - By Marguerite Chambers

NewLink Genetics Corporation (NASDAQ:NLNK) LogoInvestors sentiment increased to 1.51 in Q4 2017. Its up 0.29, from 1.22 in 2017Q3. It is positive, as 22 investors sold NewLink Genetics Corporation shares while 21 reduced holdings. 28 funds opened positions while 37 raised stakes. 23.56 million shares or 27.79% more from 18.44 million shares in 2017Q3 were reported.
Susquehanna International Gru Limited Liability Partnership accumulated 0% or 99,862 shares. Buckingham Asset Ltd Liability Corporation holds 0.03% or 19,000 shares in its portfolio. Raymond James Fincl Svcs Advisors owns 14,522 shares. Group One Trading L P invested in 15,609 shares or 0% of the stock. State Of Wisconsin Invest Board stated it has 17,000 shares or 0% of all its holdings. State Street Corp accumulated 432,593 shares. Segall Bryant & Hamill Ltd Liability Corporation owns 114,002 shares. The Massachusetts-based Fmr Ltd Llc has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Panagora Asset Incorporated invested in 0% or 155,868 shares. Sei reported 3 shares. Parallax Volatility Advisers L P stated it has 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Amg National Trust Bankshares reported 10,703 shares. Credit Suisse Ag reported 20,125 shares. First Eagle Invest Mngmt Ltd Com invested in 2.64M shares or 0.05% of the stock. Great Point Ptnrs Ltd holds 2.75% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 1.99M shares.

Analysts expect NewLink Genetics Corporation (NASDAQ:NLNK) to report $-0.55 EPS on May, 3.They anticipate $0.17 EPS change or 23.61 % from last quarter’s $-0.72 EPS. After having $-0.37 EPS previously, NewLink Genetics Corporation’s analysts see 48.65 % EPS growth. The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.49. About 780,190 shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 65.28% since April 21, 2017 and is downtrending. It has underperformed by 76.83% the S&P500.

NewLink Genetics Corporation (NASDAQ:NLNK) Ratings Coverage

Among 5 analysts covering NewLink Genetics (NASDAQ:NLNK), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. NewLink Genetics had 7 analyst reports since November 3, 2017 according to SRatingsIntel. The firm has “Neutral” rating by Cantor Fitzgerald given on Monday, April 9. Jefferies maintained the shares of NLNK in report on Friday, November 3 with “Buy” rating. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) earned “Hold” rating by SunTrust on Monday, April 9. The firm earned “Hold” rating on Friday, April 6 by Jefferies. Bank of America downgraded the stock to “Hold” rating in Friday, April 6 report. As per Monday, April 9, the company rating was downgraded by Robert W. Baird. Bank of America maintained it with “Buy” rating and $18 target in Friday, March 2 report.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $166.83 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: